Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to determine if rigosertib sodium, given orally in
the form of soft gel capsules, is safe and is associated with a reduction in the number of
blood transfusion units that are needed in patients with myelodysplastic syndrome (MDS)
classified as Low or Intermediate-1 (Int-1) (any cytogenetics) or trisomy 8 Intermediate 2
(Int-2) in the International Prognostic Scoring System (IPSS) who are transfusion-dependent.
Rigosertib will be taken on days 1 to 21 of a 21-day cycle.